Sazetidine-A has been recently proposed to be a "silent desensitizer" of ␣42 nicotinic acetylcholine receptors (nAChRs), implying that it desensitizes ␣42 nAChRs without first activating them. This unusual pharmacological property of sazetidine-A makes it, potentially, an excellent research tool to distinguish between the role of activation and desensitization of ␣42 nAChRs in mediating the central nervous system effects of nicotine itself, as well as those of new nicotinic drugs. We were surprised to find that sazetidine-A potently and efficaciously stimulated nAChR-mediated dopamine release from rat striatal slices, which is mediated by ␣42* and ␣62* subtypes of nAChR. The agonist effects on native striatal nAChRs prompted us to re-examine the effects of sazetidine-A on recombinant ␣42 nAChRs in more detail. We expressed the two alternative stoichiometries of ␣42 nAChR in Xenopus laevis oocytes and investigated the agonist properties of sazetidine-A on both ␣4(2)2(3)and ␣4(3)2(2) nAChRs. We found that sazetidine-A potently activated both stoichiometries of ␣42 nAChR: it was a full agonist on ␣4(2)2(3) nAChRs, whereas it had an efficacy of only 6% on ␣4(3)2(2) nAChRs. In contrast to what has been published before, we therefore conclude that sazetidine-A is an agonist of native and recombinant ␣42 nAChRs but shows differential efficacy on ␣42 nAChRs subtypes.
Pharmacological manipulation of specific neural circuits to optimize therapeutic index is an unrealized goal in neurology and psychiatry. AMPA receptors are important for excitatory synaptic transmission, and their antagonists are antiepileptic. Although efficacious, AMPA-receptor antagonists, including perampanel (Fycompa), the only approved antagonist for epilepsy, induce dizziness and motor impairment. We hypothesized that blockade of forebrain AMPA receptors without blocking cerebellar AMPA receptors would be antiepileptic and devoid of motor impairment. Taking advantage of an AMPA receptor auxiliary protein, TARP γ-8, which is selectively expressed in the forebrain and modulates the pharmacological properties of AMPA receptors, we discovered that LY3130481 selectively antagonized recombinant and native AMPA receptors containing γ-8, but not γ-2 (cerebellum) or other TARP members. Two amino acid residues unique to γ-8 determined this selectivity. We also observed antagonism of AMPA receptors expressed in hippocampal, but not cerebellar, tissue from an patient with epilepsy. Corresponding to this selective activity, LY3130481 prevented multiple seizure types in rats and mice and without motor side effects. These findings demonstrate the first rationally discovered molecule targeting specific neural circuitries for therapeutic advantage.
Regulatory CD4+CD25+ T cells (Tregs) suppress autoimmune and inflammatory diseases through mechanisms that are only partly understood. Previous studies suggest that Tregs can suppress bacterially triggered intestinal inflammation and respond to LPS through TLRs with enhanced suppressive activity. In this study, we have used murine cecal ligation and puncture as a model of polymicrobial sepsis to explore the effects of adoptive transfer of Tregs on septic outcome. Adoptive transfer of in vitro-stimulated Tregs in both prevention and therapeutic modes significantly improved survival of cecal ligation and puncture mice. Furthermore, the effect was dependent on both the number of Tregs adoptively transferred and the presence of host T cells. Animals that received stimulated Tregs had significantly increased peritoneal mast cells and peritoneal TNF-α production. More importantly, adoptive transfer of in vitro-stimulated Tregs significantly improved bacterial clearance, which resulted in improved survival. Our results suggest a novel role for Tregs in sepsis.
Transmembrane AMPA receptor regulatory proteins (TARPs) are a family of scaffolding proteins that regulate AMPA receptor trafficking and function. TARP γ-8 is one member of this family and is highly expressed within the hippocampus relative to the cerebellum. A selective TARP γ-8-dependent AMPA receptor antagonist (TDAA) is an innovative approach to modulate AMPA receptors in specific brain regions to potentially increase the therapeutic index relative to known non-TARP-dependent AMPA antagonists. We describe here, for the first time, the discovery of a noncompetitive AMPA receptor antagonist that is dependent on the presence of TARP γ-8. Three major iteration cycles were employed to improve upon potency, CYP1A2-dependent challenges, and in vivo clearance. An optimized molecule, compound (-)-25 (LY3130481), was fully protective against pentylenetetrazole-induced convulsions in rats without the motor impairment associated with non-TARP-dependent AMPA receptor antagonists. Compound (-)-25 could be utilized to provide proof of concept for antiepileptic efficacy with reduced motor side effects in patients.
The data from this study indicate that an early decrease in protein C concentration predicts poor outcome in a rat sepsis model. The data further indicate that increases in the CXC chemokines macrophage inflammatory protein-2 and KC precede poor outcome.
The X-linked form of chronic granulomatous disease (X-CGD), an inherited deficiency of the respiratory burst oxidase, results from mutations in the X-linked gene for gp91phox, the larger subunit of the oxidase cytochrome b. The goal of this study was to evaluate the impact of retroviral-mediated gene transfer of gp91phox on host defense against Aspergillus fumigatus in a murine model of X-CGD. Retrovirus vectors constructed using the murine stem cell virus (MSCV) backbone were used for gene transfer of the gp91phox cDNA into murine X-CGD bone marrow cells. Transduced cells were transplanted into lethally irradiated syngeneic X-CGD mice. After hematologic recovery, superoxide production, as monitored by the nitroblue tetrazolium (NBT) test, was detected in up to ≈80% of peripheral blood neutrophils for at least 28 to 35 weeks after transplantation. Neutrophil expression of recombinant gp91phox and superoxide production were significantly less than wild-type neutrophils. However, 9 of 9 mice with ≈50% to 80% NBT+ neutrophils after gene transfer did not develop lung disease after respiratory challenge with 150 to 500 A fumigatus spores, doses that produced disease in 16 of 16 control X-CGD mice. In X-CGD mice transplanted with mixtures of wild-type and X-CGD bone marrow, ≥5% wild-type neutrophils were required for protection against A fumigatus challenge. These data suggest that expression of even low levels of recombinant gp91phox can substantially improve phagocyte function in X-CGD, although correction of very small percentage of phagocytes may not be sufficient for protection against A fumigatus.
In a search for novel growth factors, we discovered that human interleukin-20 (IL-20) enhanced colony formation by CD34 ؉ multipotential progenitors. IL-20 had no effect on erythroid, granulocyte-macrophage, or megakaryocyte progenitors. IL- IntroductionCytokines are important regulators of the growth and development of hematopoietic cells 1,2 ; some are currently in clinical use. In a search for novel factors that regulate hematopoiesis, colony assays were used to screen novel secreted proteins identified through bioinformatics. One protein identified was identical to . 3,4 We demonstrate that IL-20 specifically enhances the proliferation of multipotential progenitors in vitro and in vivo without effect on more lineage-restricted progenitor cells. Study design Protein productionRecombinant human , containing a C-terminal FLAG tag (Eastman Kodak, Rochester, NY) followed by 6 histidine residues (Flis), was produced in 293EBNA1 cells. 5 We captured rhIL-20-Flis on Pharmacia Chelating Sepharose FF (Amersham-Pharmacia, Piscataway, NJ). The endotoxin level was less than 5.3 EU/mg rhIL-20. Colony assays for human and murine progenitorsCD34 ϩ human bone marrow or cord blood cells were purchased from BioWhittaker (Walkersville, MD). Colony assays for granulocytemacrophage (CFU-GM), erythroid (BFU-E), and multipotential (CFU-GEMM) progenitors were as described. 6,7 Megakaryocyte (CFU-Meg) progenitor assays were carried out using MegaCult-C medium (Stem Cell Technologies, Vancouver, BC, Canada). IL-20 transgenic miceTransgenic (TG) mice were generated by established techniques. 8 Human IL-20 was overexpressed in TG mice using apolipoprotein E gene promoter. IL-20 levels in mouse serum were determined using enzyme-linked immunosorbent assay (ELISA) with antihuman rhIL-20. rhIL-20 administration to normal miceFemale BDF1 mice (8-10 weeks of age; Harlan, Indianapolis, IN) were administered rhIL-20 (5 g/mouse) subcutaneously twice a day for 10 days. At day 11, mice were killed, bone marrow and spleen cells were counted, cells were used for colony assays, and the proportion of progenitors in S-phase of the cell cycle was estimated. 7,9,10 Results and discussion IL-20 in vitroIL-20 did not stimulate colony formation, but it increased the numbers of larger-sized colonies in combination with recombinant human stem cell factor (SCF) and erythropoietin (EPO) ( Figure 1Ai-ii). Colonies cultured with IL-20 contained cells with and without hemoglobin expression. Microscopic examination of 22 individual large colonies stained with Wright-Giemsa revealed mainly erythroblasts mixed with megakaryocytes. Granulocytes and monocytes were also detected (original magnification, ϫ 400) within these colonies but were less prominent than erythroblasts and megakaryocytes . This suggested that IL-20 enhanced CFU-GEMM.Colony assays were performed with human bone marrow (BM) and cord blood (CB) CD34 ϩ cells using various cytokine combinations. IL-20 (200 ng/mL), in combination with EPO and SCF, significantly enhanced BM CFU-GEMM numbers approximate...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.